SHAREHOLDER Notify: Pomerantz Law Agency Investigates Statements On Behalf of Buyers of Dr. Reddy’s Laboratories Restricted – RDY

NEW YORK, Feb. 2, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s” or the “Firm”) (NYSE: RDY).  These kinds of buyers are encouraged to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.

The investigation worries no matter whether Dr. Reddy’s and particular of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On January 29, 2021, Dr. Reddy’s issued a press release saying the Company’s economic results for the quarter and nine months ended December 31, 2020.  Between other final results, Dr. Reddy’s posted a decrease-than-envisioned profit for the quarter, citing the influence of “set off primarily based impairment prices taken on a couple obtained products together with gNuvaring.” 

On this news, Dr. Reddy’s American Depositary Receipt (“ADR”) price fell $4.78 for each ADR, or 7.24%, to shut at $61.28 for every ADR on January 29, 2021.

The Pomerantz Agency, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as just one of the premier corporations in the locations of corporate, securities, and antitrust course litigation. Founded by the late Abraham L. Pomerantz, recognized as the dean of the course action bar, the Pomerantz Company pioneered the subject of securities class actions. Nowadays, extra than 80 a long time later, the Pomerantz Company proceeds in the custom he set up, preventing for the rights of the victims of securities fraud, breaches of fiduciary obligation, and company misconduct. The Business has recovered quite a few multimillion-greenback damages awards on behalf of class associates. See

Robert S. Willoughby
Pomerantz LLP
[email protected]  
888-476-6529 ext. 7980


Cision See primary information:—rdy-301219672.html

Source Pomerantz LLP